
    
      OUTLINE:

      Patients receive niraparib orally (PO) once daily (QD) on days 1-28 of cycle 1. Beginning
      cycle 2, patients receive niraparib PO QD on days 1-21 and dostarlimab intravenously (IV) on
      day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or
      unacceptable toxicity. Beginning cycle 6, patients receive niraparib PO QD on days 1-42 and
      dostarlimab IV on day 1. Cycles repeat every 42 days for up to 24 months in the absence of
      disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 30 days, every 6 months for
      2 years, and then annually for up to 5 years.
    
  